| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2021-01-26 | BridgeBio Pharma, Inc. | Eidos Therapeutics, Inc. | 1,000 | 100.0% | EDGAR |
| SC 13D/A | 2021-01-26 | Eidos Therapeutics, Inc. | BridgeBio Pharma, Inc. | 0 | 0.0% | EDGAR |
| SC 13D | 2020-10-15 | Eidos Therapeutics, Inc. | BridgeBio Pharma, Inc. | 44,651,896 | 36.4% | EDGAR |
| SC 13D/A | 2020-10-06 | KKR Genetic Disorder L.P. | BridgeBio Pharma, Inc. | 34,510,971 | 28.2% | EDGAR |
| SC 13D/A | 2020-10-05 | BridgeBio Pharma, Inc. | Eidos Therapeutics, Inc. | 24,575,501 | 63.7% | EDGAR |
| SC 13D/A | 2020-06-01 | KKR Genetic Disorder L.P. | BridgeBio Pharma, Inc. | 34,510,971 | 28.4% | EDGAR |
| SC 13G/A | 2020-02-14 | PERCEPTIVE ADVISORS LLC | BridgeBio Pharma, Inc. | 6,706,268 | 5.4% | EDGAR |
| SC 13G | 2020-02-14 | AMERICAN INTERNATIONAL GROUP INC | BridgeBio Pharma, Inc. | 6,764,592 | 5.5% | EDGAR |
| SC 13G | 2020-02-14 | Kumar Neil | BridgeBio Pharma, Inc. | 8,618,783 | 7.0% | EDGAR |
| SC 13D/A | 2019-10-15 | BridgeBio Pharma, Inc. | Eidos Therapeutics, Inc. | 24,575,501 | 65.6% | EDGAR |
| SC 13D/A | 2019-08-08 | BridgeBio Pharma, Inc. | Eidos Therapeutics, Inc. | 24,575,501 | 66.6% | EDGAR |
| SC 13G | 2019-07-11 | PERCEPTIVE ADVISORS LLC | BridgeBio Pharma, Inc. | 6,586,268 | 5.5% | EDGAR |
| SC 13D | 2019-07-10 | KKR Genetic Disorder L.P. | BridgeBio Pharma, Inc. | 36,900,661 | 29.9% | EDGAR |
| SC 13D/A | 2019-07-09 | BridgeBio Pharma, Inc. | Eidos Therapeutics, Inc. | 24,575,501 | 66.7% | EDGAR |
| SC 13D | 2019-07-08 | VIKING GLOBAL INVESTORS LP | BridgeBio Pharma, Inc. | 26,620,991 | 22.1% | EDGAR |
| SC 13D/A | 2019-05-30 | BridgeBio Pharma, Inc. | Eidos Therapeutics, Inc. | 23,693,148 | 64.3% | EDGAR |
| SC 13D/A | 2018-12-13 | BridgeBio Pharma LLC | Eidos Therapeutics, Inc. | 22,589,300 | 61.5% | EDGAR |
| SC 13D/A | 2018-12-11 | BridgeBio Pharma LLC | Eidos Therapeutics, Inc. | 22,548,647 | 61.4% | EDGAR |
| SC 13D/A | 2018-12-07 | BridgeBio Pharma LLC | Eidos Therapeutics, Inc. | 22,468,503 | 61.1% | EDGAR |
| SC 13D | 2018-08-01 | BridgeBio Pharma LLC | Eidos Therapeutics, Inc. | 19,614,655 | 54.8% | EDGAR |